# US 2012/0020969 A1 · Compositions And Methods For Inhibiting Viral Adhesion

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0020969 A1
- Document ID: US20120020969A1
- Status: Published application
- Kind: A1
- Application number: 13/248,967
- Filed: 2011-09-29
- Published: 2012-01-26
- Earliest claimed: 2006-01-26
- Assignees: Recopharma AB
- Inventors: Jan Holgersson
- Web page: https://patentgrep.com/patent/US20120020969A1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61P 27/02: Ophthalmic agents
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/20: for DNA viruses
- C07K 14/4727: {Mucins, e.g. human intestinal mucin}
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12N 2796/00: Viruses not covered by groups C12N2710/00 - C12N2795/00
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides compositions and methods for treating or preventing viral infections.

## Claims

### Claim 1

A fusion polypeptide comprising a first polypeptide operably linked to a second polypeptide wherein the first polypeptide carries at least one glycan selected from the group consisting of:
a) a Siaα3Galβ4GlcNAcβ glycan,
b) a Siaα3Galβ3GlcNAcβ glycan,
c) a Siaα6Galβ4GlcNAcβ glycan,
d) a Siaα6Galβ3GlcNAcβ glycan,
e) a Fucα2Galβ3GalNAcα glycan
f) a Fucα2Galβ3GlcNAcβ glycan and
g) a Fucα2Galβ4GlcNAcβ glycan,
and the second polypeptide comprises at least a region of an immunoglobulin polypeptide.

### Claim 2 (depends on 1)

The fusion polypeptide of claim 1, wherein the first polypeptide is a mucin polypeptide.

### Claim 3 (depends on 1)

The fusion polypeptide of claim 1, wherein said glycan is terminal.

### Claim 4 (depends on 1)

The fusion polypeptide of claim 1, wherein said glycan is multivalent.

### Claim 5 (depends on 2)

The fusion polypeptide of claim 2, wherein the mucin is selected from the group consisting of PSGL-1, MUC1, MUC2, MUC3, MUC4, MUCSa, MUCSb, MUCSc, MUC6, MUC11, MUC12, CD34, CD43, CD45, CD96, GlyCAM-1, MAdCAM, or a fragment thereof.

### Claim 6 (depends on 2)

The fusion polypeptide of claim 2, wherein said mucin polypeptide comprises at least a region of a P-selectin glycoprotein ligand-1.

### Claim 7 (depends on 2)

The fusion polypeptide of claim 2, wherein said mucin polypeptide includes an extracellular portion of a P-selectin glycoprotein ligand-1.

### Claim 8 (depends on 1)

The fusion polypeptide of claim 1, wherein the first polypeptide is an alpha glycoprotein polypeptide.

### Claim 9 (depends on 1)

The fusion polypeptide of claim 1, wherein the first polypeptide comprises at least a region of an alpha-1-acid glycoprotein.

### Claim 10 (depends on 1)

The fusion polypeptide of claim 1, wherein the second polypeptide comprises a region of a heavy chain immunoglobulin polypeptide.

### Claim 11 (depends on 1)

The fusion polypeptide of claim 1, wherein said second polypeptide comprises an Fc region of an immunoglobulin heavy chain.

### Claim 12 (depends on 1)

A method of decreasing adhesion of a virus to a cell, comprising contacting the virus with the fusion polypeptide of claim 1.

### Claim 13 (depends on 1)

A method of preventing viral or alleviating a symptom of viral infection in a subject in need thereof comprising administering to the subject the fusion polypeptide of claim 1.

### Claim 14 (depends on 12)

The method of claim 12, wherein the virus is an oculotropic virus, a human influenza virus, an avian influenza virus, a recombination of a human and an avian influenza virus, or a Norovirus.

### Claim 15 (depends on 14)

The method of claim 14, wherein said oculotrophic virus is an adenovirus 37, an enterovirus 70 or an avian influenza virus.

### Claim 16 (depends on 1)

A cell genetically engineered to produce the fusion polypeptide of claim 1.